NEPH· Health Care› Medical Instruments & Supplies

Nephros, Inc.

Stage 3 · Topping · week 1

As of Oct 22, 2026, Nephros is in Stage 3, the topping phase, now in its first week (since Oct 21, 2026). It closed at $3.52, 39.2% below its 52-week high and below its 200-day average, which is falling.

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. More about the company

$3.52

-1.95% today

$38.2M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is NEPH early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 23w

S4 35w

S2 36w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 2w → S3 5w → S2 23w → S3 7w → S4 35w → S1 7w → S4 4w → S1 5w → S2 36w → S3 9w → S4 13w → S1 13w → S2 6w → S3 1w current

Total tracked: 165 weeks across 14 stage runs.

NEPH among Medical Instruments & Supplies35th of 51 by relative strength

All 51 →

Stocks in Medical Instruments & Supplies ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	PLSEPulse Biosciences, Inc	Stage 2 · wk 34	98	+1.3%
2	PDEXPro-Dex, Inc.	Stage 2 · wk 36	97	−13.3%
3	HBIOHarvard Bioscience, Inc.	Stage 2 · wk 11	95	+3.6%
4	ATRCAtriCure, Inc.	Stage 2 · wk 10	89	−1.1%
5	WSTWest Pharmaceutical Services, Inc.	Stage 2 · wk 24	82	+4.8%
6	BDXBecton, Dickinson and Company	Stage 2 · wk 11	81	+9.8%
7	ICUIICU Medical, Inc.	Stage 3 · wk 1	81	+3.1%
8	OSUROraSure Technologies, Inc.	Stage 3 · wk 8	75	−4.8%
…35	NEPHNephros, Inc.	Stage 3 · wk 1	35	−17.9%

vs 52W High

-39.2%

$2.78 lo$5.79 hi

39.2% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-5.1%

200 DMA: $3.71 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.12x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-17.9%

-3.3%

+23.9%

YTD

-25.9%

-27.4%

Scan Membership

Breakout Watch

Latest: 2025-04-28

8 appearances in last 60 days. First seen: 2018-12-10.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 0.12x

2026-10-21S32→3

Wk 1 · Vol 0.34x

2026-10-20S2

Wk 6 · Vol 1.18x

2026-10-19S2

Wk 6 · Vol 1.35x

2026-10-16S2

Wk 6 · Vol 1.33x

2026-10-15S2

Wk 6 · Vol 0.77x

2026-10-14S2

Wk 6 · Vol 0.27x

2026-10-13S2

Wk 5 · Vol 0.59x

2026-10-12S2

Wk 5 · Vol 2.00x

2026-10-09S2

Wk 5 · Vol 1.09x

2026-10-08S2

Wk 5 · Vol 4.44x

2026-10-07S2

Wk 5 · Vol 1.54x

Moving averages & range

50 DMA

$4.04

200 DMA

$3.71

52W High

$5.79

52W Low

$2.78

5D Low

$3.52

Resistance levels (recent highs)

20d High

$4.23

60d High

$4.76

120d High

$4.76

250d High

$5.79

Next resistance

+20.2%

to 20d High

P/E (TTM)

23.5

Forward 16.8

Earnings Growth (YoY)

+450.0%

Revenue +36.2%

ROE

+16.1%

Profit margin +8.4%

Dividend Yield

0.00%

P/B 3.2

Nephros: quick answers

What stage is Nephros in?

As of Oct 22, 2026, Nephros (NEPH) is in Stage 3, the topping phase. It entered Stage 3 on Oct 21, 2026 and is in its first week there. What the four stages mean

Is Nephros in an uptrend?

Its uptrend has stalled. Nephros is in Stage 3, the topping phase that follows an advance. It trades 5.1% below its 200-day average, which is falling.

How far is Nephros from its 52-week high?

Nephros closed at $3.52 on Oct 22, 2026, 39.2% below its 52-week high of $5.79. Its 52-week low is $2.78.

How has Nephros performed over the past year?

As of Oct 22, 2026, Nephros is down 27.4% over the past year and down 25.9% so far in 2026.

Which sector and industry is Nephros in?

Nephros is in the Medical Instruments & Supplies industry, part of the Health Care sector.

About this companyHealth Care· Medical Instruments & Supplies

Nephros, Inc., a commercial-stage company, develops and sells water filtration solutions for medical and commercial applications in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in foodservice and hospitality, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water; reduce biofilm and scale build-up; and remove cysts, particulates, and lead from water systems. It markets its products to food service and hospitality sectors including quick-service restaurants, convenience stores, and restaurants. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.